Cargando…

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige(®)) versus placebo and celecoxib in patients with knee osteoarthritis. This seven day, double-blind, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wittenberg, Ralf H, Schell, Ernest, Krehan, Gerhard, Maeumbaed, Roland, Runge, Hans, Schlüter, Peter, Fashola, Taiwo OA, Thurston, Helen J, Burger, Klaus J, Trechsel, Ulrich
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526611/ https://www.ncbi.nlm.nih.gov/pubmed/16469112 http://dx.doi.org/10.1186/ar1854

Ejemplares similares

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis
por: Geusens, Piet, et al.
Publicado: (2008)

Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison
por: Stam, WB, et al.
Publicado: (2012)

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells
por: Basu, Gargi D, et al.
Publicado: (2005)

Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
por: Profit, Louise, et al.
Publicado: (2007)

Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis
por: Dougados, Maxime, et al.
Publicado: (2007)

Preemptive versus postoperative lumiracoxib for analgesia in ambulatory arthroscopic knee surgery
por: Grifka, Joachim, et al.
Publicado: (2008)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis
por: Mackenzie, Isla S., et al.
Publicado: (2012)

The Role of Potassium Channel Activation in Celecoxib-Induced Analgesic Action
por: Mi, Yao, et al.
Publicado: (2013)

Cyclooxygenase-1-selective inhibitor SC-560
por: Long, Sihui, et al.
Publicado: (2009)

Comparative QSAR analysis of cyclo-oxygenase2 inhibiting drugs
por: Mohanapriya, Arumugam, et al.
Publicado: (2012)

Biological Screening of Novel Structural Analog of Celecoxib as Potential Anti-Inflammatory and Analgesic Agent
por: Zlatanova, Hristina, et al.
Publicado: (2019)

BALB.NCT-Cpox(nct) is a unique mouse model of hereditary coproporphyria
por: Kang, Xiaojing, et al.
Publicado: (2023)

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer
por: Connolly, E M, et al.
Publicado: (2002)

Specific desensitization of the canine renal vasculature to angiotensin II despite cyclo-oxygenase inhibition.
por: Meggs, L. G., et al.
Publicado: (1985)

Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity
por: Jones, D J L, et al.
Publicado: (2004)

Synthesis and Characterization of Celecoxib Derivatives as Possible Anti-Inflammatory, Analgesic, Antioxidant, Anticancer and Anti-HCV Agents †
por: Küçükgüzel, Ş. Güniz, et al.
Publicado: (2013)

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer
por: Leung, W K, et al.
Publicado: (2001)

The association between cyclo-oxygenase-2 expression and cell proliferation and angiogenesis in human breast cancer
por: Kirkpatrick, K, et al.
Publicado: (2001)

Cyclo-Oxygenase 2 Modulates Chemoresistance in Breast Cancer Cells Involving NF-κB
por: Zatelli, Maria Chiara, et al.
Publicado: (2009)

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
por: Stricker, Kirstin, et al.
Publicado: (2008)

Comparison of the analgesic effect of inhaled lavender vs vanilla essential oil for neonatal frenotomy: a randomized clinical trial (NCT04867824)
por: Maya-Enero, Silvia, et al.
Publicado: (2022)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk
por: Moore, R Andrew, et al.
Publicado: (2007)

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.
por: Tjandrawinata, R. R., et al.
Publicado: (1997)

The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall
por: de Jongh, R, et al.
Publicado: (2009)

Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
por: Mirabito Colafella, Katrina M., et al.
Publicado: (2022)

Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study
por: Hensley, Abigail, et al.
Publicado: (2015)

Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?
por: Khan, Shanzana, et al.
Publicado: (2019)

Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation
por: Keränen, Sara, et al.
Publicado: (2021)

Schweizerisches Strafrecht
por: Trechsel, Stefan
Publicado: (1994)

Involvement of Heme Oxygenase-1 Participates in Anti-Inflammatory and Analgesic Effects of Aqueous Extract of Hibiscus taiwanensis
por: Liu, Shu-Ling, et al.
Publicado: (2012)

The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor
por: Lau, C. S., et al.
Publicado: (1992)

Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study
por: Mastbergen, Simon C, et al.
Publicado: (2006)

Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor
por: Fisher, Jason C, et al.
Publicado: (2011)

TREM-1 Is Induced in Tumor Associated Macrophages by Cyclo-Oxygenase Pathway in Human Non-Small Cell Lung Cancer
por: Yuan, Zhihong, et al.
Publicado: (2014)

Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis
por: Cui, Chun-Hui, et al.
Publicado: (2015)

Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
por: Sobolewski, Cyril, et al.
Publicado: (2021)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner
por: Ciorba, Matthew A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2fl2mge4p5kksilhd30mjoobfq